L. Bradford

2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity.

D. Boschelli, A. Doherty, H. D. Showalter, 1998, Journal of medicinal chemistry.

Structure-activity relationships for a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors.

A. Doherty, D. W. Fry, H. D. Showalter, 1997, Journal of medicinal chemistry.

Synthesis and tyrosine kinase inhibitory activity of a series of 2-amino-8H-pyrido[2,3-d]pyrimidines: identification of potent, selective platelet-derived growth factor receptor tyrosine kinase inhibitors.

D. Boschelli, A. Doherty, H. D. Showalter, 1998, Journal of medicinal chemistry.

Low-dose phenobarbitone as an indicator of compliance with drug therapy.

M. Feely, S. Singleton, D. Price, 1987, British journal of clinical pharmacology.

2-Substituted Aminopyrido[2,3- d ]pyrimidin-7(8 H )-ones. Structure−Activity Relationships Against Selected Tyrosine Kinases and in Vitro and in Vivo Anticancer Activity

D. Boschelli, A. Doherty, H. D. Showalter, 1998 .

Liquid chromatographic assay for a butenolide endothelin antagonist (PD 156707) in plasma.

D. T. Rossi, H. Hallak, L. Bradford, 1996, Journal of chromatography. B, Biomedical applications.

Endothelin A receptor antagonism by PD 156707 does not reduce infarct size after coronary artery occlusion/reperfusion in pigs.

K. Gallagher, P. Juneau, H. Hallak, 1996, Journal of Pharmacology and Experimental Therapeutics.